Irinotecan for children with relapsed solid tumors |
| |
| Authors: | Shitara Toshiji Shimada Akira Hanada Ryoji Matsunaga Tadashi Kawa Keisei Mugishima Hideo Sugimoto Tohru Mimaya Jun-ichi Manabe Atsushi Tsurusawa Masahito Tsuchida Yoshiaki |
| |
| Institution: |
a Department of Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan
b Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan
c Department of Pediatric Surgery, Chiba University School of Medicine, Chiba, Japan
d Department of Hematology/Oncology, Osaka Medical Center for Maternity and Child Health, Osaka, Japan
e Department of Pediatrics, Nihon University School of Medicine, Tokyo, Japan
f Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan
g Department of Hematology/Oncology, Shizuoka Children's Hospital, Shizuoka, Japan
h Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan
i Department of Pediatrics, Aichi Medical College, Aichi, Japan |
| |
| Abstract: | Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuro-blastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment. |
| |
| Keywords: | clinical trials irinotecan nephroblastoma neuroblastoma rhabdomyosarcoma |
| 本文献已被 InformaWorld PubMed 等数据库收录！ |
|
